

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

| Complete if Known | |
|------------------------|------------------|
| Application Number | 10/519,110 |
| Filing Date | July 2, 2003 |
| First Named Inventor | Etcheberrigaray |
| Art Unit | Not Yet Assigned |
| Examiner Name | Not Yet Assigned |
| Attorney Docket Number | 17357.01001US |

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | |
| | | JP 279311 | 03/26/1993 | | |
| | | JP 240581 | 02/29/2000 | | |
| | | JP 406279311A | 10/04/1994 | Tamura et al. | |
| | | WO 2004/004641 A2 | 01/15/2004 | Etcheberrigarary et al. | |
| | | WO 97/43268 | 11/20/1997 | Kozikowski | |

| | | | |
|-----------------------|-----------------|--------------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|-----------------------|-----------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /SW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

| | | | |
|--|---|------------------------|---------------|
| Substitute for form 1449/PTO | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (Use as many sheets as necessary) | | | |
| Sheet | 2 | of | |
| | | Attorney Docket Number | 17357.01001US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | | Alkon, D.L. et al. "Regulation of Hermissenda K+ Channels by Cytoplasmic and Membrane-Associated C-Kinase," J. Neurochem., Vol. 51, No. 3, 1988 | |
| | | Bennett, Brian D., et al. "Expression Analysis of BACE2 in Brain and Peripheral Tissues," The Journal of Biological Chemistry, Vol. 275, No. 27, Issue of July 7, pp. 29647-20651, 2000 | |
| | | Bergamaschi, Stefania, et al. "Defective phorbol ester-stimulated secretion of B-amyloid precursor protein from Alzheimer's disease fibroblasts," Neuroscience Letters 201(1995) 1-4 | |
| | | Bondy, Brigitta, et al. "The PHA-Induced Calcium Signal in Lymphocytes is Altered After Blockade of K+-Channels in Alzheimer's Disease," J. Psychiat. Res. Vol. 30, No. 3, pp. 217-227, 1996 | |
| | | Burke, James R., et al. "Update on Alzheimer's Disease: Promising advances in detection and treatment," Postgraduate Medicine, Vol. 106, No. 5, October 15, 1999 | |
| | | Bury, Richard W. "PKC Activators (Phorbol Ester or Bryostatin) Stimulate Outgrowth of NGF-Dependent Neurites in a Subline of PC12 Cells," Journal of Neuroscience Research, 53:214-22 (199) | |
| | | Buxbaum, Joseph D., et al. "Evidence That Tumor Necrosis Factor a Converting Enzyme Is Involved In Regulated a-Secretase Cleavage of the Alzheimer Amyloid Protein Precursor," The Journal of Biological Chemistry, Vol. 273, No. 43, Issue of October 23, pp. 27765-27767, 1998 | |
| | | Cai, Huaibin, et al. "BACE1 is the major B-secretase for generation of AB peptides by neurons," Nature Neuroscience, Vol. 4, No. 3, March 2001 | |
| | | Caputi, A.. et al. "Increased Secretion of the Amino-Terminal Fragment of Amyloid Precursor Protein in Brains of Rats with a Constitutive Up-Regulation of Protein Kinase C," J. Neurochem., Vol. 68, No. 6, 1997 | |
| | | Cole, Gregory, et al. "Decreased levels of protein kinase C in Alzheimer brain," Brain Research, 452 (1988) 165-174 | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

| | | | |
|--|---|----|------------------------|
| Substitute for form 1449/PTO | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (Use as many sheets as necessary) | | | |
| Sheet | 3 | of | |
| | | | Attorney Docket Number |
| | | | 17357.01001US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | | Connolly, Gerald P. "Fibroblast models of neurological disorders: fluorescence measurement studies," TIPS - May 1998 (Vol. 19) | |
| | | Coughlan, Christine, et al. "Factors influencing the processing and function of the amyloid B precursor protein - a potential therapeutic target in Alzheimer's disease?," Pharmacology & Therapeutics 86 (2000) 111-144 | |
| | | Desdouits, Frederic, et al. "Amyloid B Peptide Formation in Cell-free Preparations," The Journal of Biological Chemistry, Vol. 271, No. 40, Issue of October 4, pp. 24670-24674, 1996 | |
| | | Efthimiopoulos, Spiros, et al. "Intracellular Cyclic AMP Inhibits Constitutive and Phorbol Ester-Stimulated Secretory Cleavage of Amyloid Precursor Protein," J. Neurochem. Vol. 67, No. 2, 1996 | |
| | | Esler, William, et al. "A Portrait of Alzheimer Secretases - New Features and Familiar Faces," Science, Vol. 293, 24 August 2001 | |
| | | Etcheberrigaray, Rene, et al. "Calcium responses are altered in fibroblasts from Alzheimer's patients and pre-symptomatic PS1 carriers: a potential tool for early diagnosis," Research Report, Alzheimer's Report, Vol. 3, Nos. 5 & 6, pp. 305-312 (2000) | |
| | | Favit, Antonella et al. "Alzheimer's-specific effects of soluble B-amyloid on protein kinase C- α and - γ degradation in human fibroblasts," Proc. Natl. Acad. Sci. USA Vol. 95, pp. 5562-5567, May 1998 Cell Biology | |
| | | Gabuzda, Dana et al. "Inhibition of B-Amyloid Production by Activation of Protein Kinase C," J. Neurochem. Vol. 61, No. 6, 1993 | |
| | | Gillespie, Susan L., et al. "Secretory Processing of the Alzheimer Amyloid B/A4 Protein Precursor is Increased by Protein Phosphorylation," Biochemical and Biophysical Research Communications, Vol. 187, No. 3, 1992 | |
| | | Ghosh, Arun, et al. "Design of Potent Inhibitors for Human Brain Memapsin 2 (B-Secretase)," J. Am. Chem. Soc. 2000, 122, 3522-3523 | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

| | | | |
|--|---|----|------------------------|
| Substitute for form 1449/PTO | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (Use as many sheets as necessary) | | | |
| Sheet | 4 | of | |
| | | | Attorney Docket Number |
| | | | 17357.01001US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | | Goekjian, Peter G., et al. "Protein Kinase C in the Treatment of Disease: Signal Transduction Pathways, Inhibitors, and Agents in Development," Current Chemistry, 1999, 6, 877-903 | |
| | | Govoni, S., et al. "Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation," Neurology 1996; 46:1069-1075 | |
| | | Govoni, S., et al. "Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients," Neurology 1993; 43:2581-2586 | |
| | | Haniu, Mitsuru, et al. "Characterization of Alzheimer's B-Secretase Protein BACE," The Journal of Biological Chemistry, Vol. 275, No. 28, Issue of July 14, pp. 21099-21106, 2000 | |
| | | Hardy, John "Amyloid, the presenilins and Alzheimer's disease," TINS, Vol. 20, No. 4, 1997 | |
| | | Hennings, Henry, et al. "Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin," Carcinogenesis, 8(9): 1343-1346 (1987) | |
| | | Hofmann, Johann "The potential for isoenzyme-selective modulation of protein kinase C," The FASEB Journal, Vol. 11, July 1997 | |
| | | Hung, Albert Y, et al. "Activation of Protein Kinase C Inhibits Cellular Production of the Amyloid B-Protein," The Journal of Biological Chemistry, Vol. 268, No. 31, Issue of November 5, pp. 22959-22962, 1993 | |
| | | Huynh, Tuan Van, et al. "Reduced Protein Kinase C Immunoreactivity and Altered Protein Phosphorylation in Alzheimer's Disease Fibroblasts," Arch Neurol - Vol. 46, November 1999 | |
| | | Ibarreta, Dolores, et al. "Benzolactam (BL) enhances sAPP secretion in fibroblasts and in PC12 cells," NeuroReport 10, 1035-1040 (1999) | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

Complete if Known

| | |
|-----------------------------|------------------|
| Application Number | 10/519,110 |
| Filing Date | July 2, 2003 |
| First Named Inventor | Etcheberrigaray |
| Art Unit | Not Yet Assigned |
| Examiner Name | Not Yet Assigned |

Attorney Docket Number 17357.01001US

NON PATENT LITERATURE DOCUMENTS

| | | | |
|--------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | Jin, Lee-Way, et al. "Changes in Protein Kinases in Brain Aging and Alzheimer's Disease," Drugs & Aging, 6(2) 1995 | |
| | | Jolly-Tornetta, Camille, et al. "Protein Kinase C Regulation of Intracellular and Cell Surface Amyloid Precursor Protein (APP) Cleavage in CHO695 Cells," Biochemistry 2000, 39, 15282-15290 | |
| | | Jolly-Tornetta, Camille, et al. "Regulation of Amyloid Precursor Protein (APP) by Protein Kinase Ca in Human Ntera 2 Neurons (NT2N)," Biochemistry 2000, 39, 7428-7435 | |
| | | Kinouchi, Tadatoshi et al. "Conventional protein kinase C (PKC)-a and novel PKCe, but not -s, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts," FEBS Letters 364 (1995) 203-206 | |
| | | Kozikowski, Alan P., et al. "Modeling, Chemistry, and Biology of the Benzolactam Analogues of Indolactam V (ILV). 2. Identification of the Binding Site of the Benzolactams in the CRD2 Activator-Binding Domain in PKCs and Discovery of an ILV Analogue of Improved Isozyme Selectivity," J. Med. Chem. 1997, 40, 1316-1326 | |
| | | Maiorini, A.F., et al. "Potential novel targets for Alzheimer pharmacotherapy: I. Secretase," Journal of Clinical Pharmacy and Therapeutics (2002) 27, 169-183 | |
| | | Masilah, E., et al. "Protein Kinase C Alteration Is An Early Biochemical Marker In Alzheimer's Disease," The Journal of Neuroscience, September 1991, 11(9): 2759-2676 | |
| | | Masilah, Eliezer "Role of Amyloid Precursor Protein in the Mechanisms of Neurodegeneration in Alzheimer's Disease," Laboratory Investigation, September 1997, Vol. 77, No. 3, p. 197 | |
| | | Hardy, J. "Molecular genetics of Alzheimer's disease," Acta Neurol Scand 1996: Supplement 165: 13-17 | |
| | | Mutter, Roger et al. "Chemistry and Clinical Biology of the Bryostatins," Bioorganic & Medicinal Chemistry 8 (2000) 1841-1860 | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

| | | | |
|--|---|----|------------------------|
| Substitute for form 1449/PTO | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | |
| (Use as many sheets as necessary) | | | |
| Sheet | 6 | of | |
| | | | Attorney Docket Number |
| | | | 17357.01001US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | | Nan, Fajun et al. "Dual Function Glutamate-Related Ligands: Discovery of a Novel, Potent Inhibitor of Glutamate Carboxypeptidase II Possessing mGluR3 Agonist Activity," Journal of Medicinal Chemistry, 43 (5): 772-774 | |
| | | Neurology of Disease. Experimental Neurology, Part B, Vol. 5, No. 3, September 1998 | |
| | | RobNer, S., et al. "Short Communication. Protein kinase Ca and B1 isoforms are regulators of a-secretory proteolytic processing of amyloid precursor protein in vivo," European Journal of Neuroscience, Vol. 13, pp. 1644-1648, 2001 | |
| | | Savage, Mary J., et al. "Turnover of Amyloid B-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester," The Journal of Neuroscience, March 1, 1998, 18(5): 1743-1752 | |
| | | Scheuner, D., et al. "Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease," Nature Medicine, Vol. 2, No. 8, August 1996 | |
| | | Selkoe, Dennis J. "Alzheimer's Disease: Genes, Proteins, and Therapy," Pharmacological Review, Vol. 81, No. 2, April 2001 | |
| | | Selkoe, Dennis J. "Normal and Abnormal Biology of the B-Amyloid Precursor Protein," Annu. Re. Neurosci. 1994, 17:489-517 | |
| | | Selkoe, Dennis J. "Translating cell biology into therapeutic advances in Alzheimer's disease," Nature, Vol. 399, Supp. 34 June 1999 | |
| | | Shimohama, S., et al. "Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease," Neurology 1993: 43:1407-1413 | |
| | | Shoulson, Ira "Experimental Therapeutics of neurodegenerative Disorders: Unmet Needs," Science, Vol. 282, 6 November 1998 | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|------------------------------|---|----|--|-------------------------------|------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| | | | | Application Number | 10/519,110 |
| | | | | Filing Date | July 2, 2003 |
| | | | | First Named Inventor | Etcheberrigaray |
| | | | | Art Unit | Not Yet Assigned |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 7 | of | | Attorney Docket Number | 17357.01001US |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| | | Sinha, Sukanto et al. "Purification and cloning of amyloid precursor protein B-secretase from human brain," Nature, Vol. 402, 2 December 1999 | |
| | | Skovronsky, Daniel M., et al. "Protein Kinase C-dependent a-Secretase Competes with B-Secretase for Cleavage of Amyloid- B Precursor Protein in the Trans-Golgi Network," The Journal of Biological Chemistry, Vol. 275, No. 4, Issue of January 28, pp. 2568-2575, 2000 | |
| | | Small, David H., et al. "Alzheimer's Disease and the Amyloid B Protein: What Is The Role of Amyloid?" Journal of Neurochemistry, Vol. 73, No. 2, 1999 | |
| | | Szallasi, Zoltan et al. "Differential Regulation of Protein Kinase C Isozymes by Bryostatin 1 and Phorbol 12-Myristate 13-Acetate in NIH 3T3 Fibroblasts," Jornal of Biochemistry, Vol. 269, No. 3, Issue of January 21, pp. 2118-2124, 1994 | |
| | | Tanzi, Rudolph E., et al. "The Gene Defects Responsible for Familial Alzheimer's Disease," Neurology of Disease 3, 159-168 (1996) Article No. 0016 | |
| | | Turner, Robert T., et al. "Specificity of Memapsin 1 and Its Implications on the Design of Memapsin 2 (B-Secretase) Inhibitor Selectivity," Biochemistry 2002, 41, 8742-8746 | |
| | | Varteresian, Mary L., et al. "Phase II Trial of Bryostatin 1 in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia," Clinical Cancer Research, Vol. 6, 825-828, March 2000 | |
| | | Vassar, Robert et al. "AB-Generating Enzymes: Recent Advances in B- and y-Secretase Research, Neuron, Vol. 27, 419-422, September 2000 | |
| | | Vassar, Robert et al. "B-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," Science, Vol. 286, 22 October 1999 | |
| | | Wang, Hoau et al. "Attenuated Protein Kinase C Activity and Translocation in Alzheimer's Disease Brain," Neurobiology of Aging, Vol. 15, No. 3, pp. 293-298, 1994 | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SW/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8

of

Attorney Docket Number

17357.01001US

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|----------------|
| | | Webb, Benjamin L.J., et al. "Protein kinase C isoforms: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis," British Journal of Pharmacology (2000) 130, 1433-1452 | |
| | | Wiltfang, Jens et al. "Molecular Biology of Alzheimer's Dementia and Its Clinical Relevance to Early Diagnosis and New Therapeutic Strategies," Gerontology 2001; 47:65-71 | |
| | | Xu, Huaxi et al. "Metabolism of Alzheimer B-Amyloid precursor protein: Regulation by protein kinase A in intact cells and in a cell-free system," Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 4081-4084, April 1996 | |
| | | Zhang, Xueshu et al. "Preclinical Pharmacology of the Natural Product Anticancer Agent Bryostatin 1, an Activator of Protein Kinase C1," Cancer Research 56, 802-808, February 1996 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-----------------|-----------------|------------|
| Examiner Signature | /Shengjun Wang/ | Date Considered | 07/02/2009 |
|--------------------|-----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SW/